Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 4/2017

01-04-2017 | Nuclear Medicine

The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin

Authors: Philipp M. Kazmierczak, Axel Rominger, Vera Wenter, Christine Spitzweg, Christoph Auernhammer, Martin K. Angele, Carsten Rist, Clemens C. Cyran

Published in: European Radiology | Issue 4/2017

Login to get access

Abstract

Objectives

To quantify the additional value of 68Ga-DOTA-TATE PET/CT in comparison with contrast-enhanced CT alone for primary tumour detection in neuroendocrine cancer of unknown primary (CUP-NET).

Methods

In total, 38 consecutive patients (27 men, 11 women; mean age 62 years) with histologically proven CUP-NET who underwent a contrast-enhanced 68Ga-DOTA-TATE PET/CT scan for primary tumour detection and staging between 2010 and 2014 were included in this IRB-approved retrospective study. Two blinded readers independently analysed the contrast-enhanced CT and 68Ga-DOTA-TATE PET datasets separately and noted from which modality they suspected a primary tumour. Consensus was reached if the results were divergent. Postoperative histopathology (24 patients) and follow-up 68Ga-DOTA-TATE PET/CT imaging (14 patients) served as the reference standards and statistical measures of diagnostic accuracy were calculated accordingly.

Results

The majority of confirmed primary tumours were located in the abdomen (ileum in 19 patients, pancreas in 12, lung in 2, small pelvis in 1). High interobserver agreement was noted regarding the suspected primary tumour site (Cohen’s k 0.90, p < 0.001). 68Ga-DOTA-TATE PET demonstrated a significantly higher sensitivity (94 % vs. 63 %, p = 0.005) and a significantly higher accuracy (87 % vs. 68 %, p = 0.003) than contrast-enhanced CT.

Conclusions

Ga-DOTA-TATE PET/CT compared with contrast-enhanced CT alone provides an improvement in sensitivity of 50 % and an improvement in accuracy of 30 % in primary tumour detection in CUP-NET.

Key Points

• 68Ga-DOTA-TATE PET augments the sensitivity of contrast-enhanced CT by 50 %
• 68Ga-DOTA-TATE PET augments the accuracy of contrast-enhanced CT by 30 %
• Somatostatin receptor-targeted hybrid imaging optimizes primary tumour detection in CUP-NET
Literature
1.
2.
3.
Massard C, Loriot Y, Fizazi K (2011) Carcinomas of an unknown primary origin – diagnosis and treatment. Nat Rev Clin Oncol 8:701–710CrossRefPubMed
4.
Hemminki K, Bevier M, Hemminki A, Sundquist J (2012) Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 23:1854–1863CrossRefPubMed
5.
Kazmierczak PM, Nikolaou K, Rominger A, Graser A, Reiser MF, Cyran CC (2014) Radiological diagnostics in CUP syndrome. Radiologe 54:117–123CrossRefPubMed
6.
Moller AK, Loft A, Berthelsen AK et al (2012) A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 17:1146–1154CrossRefPubMedPubMedCentral
7.
Karsell PR, Sheedy PF 2nd, O'Connell MJ (1982) Computed tomography in search of cancer of unknown origin. JAMA 248:340–343CrossRefPubMed
8.
Lee JR, Kim JS, Roh JL et al (2015) Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging – prospective study. Radiology 274:764–771CrossRefPubMed
9.
Elboga U, Kervancioglu S, Sahin E, Basibuyuk M, Celen YZ, Aktolun C (2014) Utility of F-18 fluorodeoxyglucose positron emission tomography/computed in carcinoma of unknown primary. Int J Clin Exp Pathol 7:8941–8946PubMedPubMedCentral
10.
Han A, Xue J, Hu M, Zheng J, Wang X (2012) Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Cancer Epidemiol 36:470–475CrossRefPubMed
11.
Pape UF, Perren A, Niederle B et al (2012) ENETS Consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95:135–156CrossRefPubMed
12.
Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455CrossRefPubMed
13.
Bergsland EK, Nakakura EK (2014) Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg 149:889–890CrossRefPubMed
14.
Kjaer A, Knigge U (2015) Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol 50:740–747PubMedPubMedCentral
15.
Rossana B, Silvia R, Mariangela T et al (2016) Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy – a literature review. Crit Rev Oncol Hematol 98:264–274CrossRef
16.
Alonso O, Rodriguez-Taroco M, Savio E, Bentancourt C, Gambini JP, Engler H (2014) (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann Nucl Med 28:638–645CrossRefPubMed
17.
Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516CrossRefPubMed
18.
Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP (2005) Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32:478–485CrossRefPubMed
19.
Naswa N, Sharma P, Kumar A et al (2012) (68)Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med 37:245–251CrossRefPubMed
20.
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67–77CrossRefPubMed
21.
Ambrosini V, Nanni C, Zompatori M et al (2010) (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37:722–727CrossRefPubMed
22.
Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021CrossRefPubMed
23.
Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894CrossRefPubMed
24.
Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997CrossRefPubMed
25.
Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M (2011) Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology 93:223–229CrossRefPubMed
26.
Caplin ME, Baudin E, Ferolla P et al (2015) Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26:1604–1620CrossRefPubMed
27.
Johnbeck CB, Knigge U, Kjaer A (2014) PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 10:2259–2277CrossRefPubMed
28.
Kabasakal L, Demirci E, Ocak M et al (2012) Comparison of (68)Ga-DOTATATE and (68)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39:1271–1277CrossRefPubMed
29.
Kwee TC, van Ufford HM, Beek FJ et al (2009) Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 44:683–690CrossRefPubMed
30.
Look Hong NJ, Petrella T, Chan K (2015) Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. J Surg Oncol 111:423–430CrossRefPubMed
31.
Baur AD, Pavel M, Prasad V, Denecke T (2016) Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiol 57:260–270CrossRefPubMed
32.
Ruf J, Schiefer J, Furth C et al (2011) 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 52:697–704CrossRefPubMed
33.
Manfredi R, Bonatti M, Mantovani W et al (2013) Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol 23:3029–3039CrossRefPubMed
Metadata
Title
The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin
Authors
Philipp M. Kazmierczak
Axel Rominger
Vera Wenter
Christine Spitzweg
Christoph Auernhammer
Martin K. Angele
Carsten Rist
Clemens C. Cyran
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 4/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4475-3

Other articles of this Issue 4/2017

European Radiology 4/2017 Go to the issue

Chest

Detection of pulmonary fat embolism with dual-energy CT: an experimental study in rabbits

Computed Tomography

Endoleak detection using single-acquisition split-bolus dual-energy computer tomography (DECT)

Computed Tomography

Noninvasive evaluation of global and regional left ventricular function using computed tomography and magnetic resonance imaging: a meta-analysis

Ultrasound

Usefulness of combined use of contrast-enhanced ultrasound and TI-RADS classification for the differentiation of benign from malignant lesions of thyroid nodules

Computed Tomography

Prediction of presence of kidney disease in patients undergoing intravenous iodinated contrast enhanced computed tomography: a validation study

Cardiac

The effect of blood pressure on non-invasive fractional flow reserve derived from coronary computed tomography angiography